Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

AB Science will be granted a patent, valid through 2040, covering the medical use of masitinib as a treatment for sickle cell ...

Hydroxyurea remains effective long-term in reducing emergency department visits and hospital days for children living with ...

Doctors and researchers at the University of Nebraska Medical Center are hoping to bring a different therapy that uses a ...

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL ...

Gene editing technologies have cemented their place as a valued method in the biological toolkit used by researchers around the globe.

Bluebird Bio and Xcellbio have entered into an agreement to support the commercialization of sickle cell gene therapy ...

Director, Paediatrics, Jaslok Hospital & Research Centre explains how stem cell therapy and regenerative medicine have the ...

the first CRISPR/Cas9 gene-editing therapy in the UAE. This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion ...

the first CRISPR/Cas9 gene-editing therapy in the UAE. This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion ...

The backstory: Sickle cell anemia is caused by misshapen red blood ... s often out of reach for patients of color. This new gene therapy eliminates the need for a donor and offers a safer, more ...